Published Research Findings
MUCH PRE-CLINICAL SCIENTIFIC WORK HAS BEEN CARRIED OUT ON THE THERAPY, RESULTING IN NUMEROUS PUBLICATIONS, THE MOST SIGNIFICANT OF WHICH ARE:
Ni Y, et al. Necrosis avid contrast agents: functional similarity versus structural diversity. Investigative Radiology. 2005; 40: 526–535.
Ni Y. Metalloporphyrins and functional analogues as MRI contrast agents. Current Medical Imaging Reviews (CMIR) 2008; 4: 96-112.
Ni Y et al. First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent. Eur J Nucl Med Mol. 2006; 33:595–601.
Fonge H et al. Non-invasive detection and quantification of acute myocardial infarction in rabbits using mono-[123I]iodohypericin microSPECT. Eur Heart J. 2008; 29:260-9.
Miranda Cona M, et al. Necrosis avidity of organic compounds: a natural phenomenon with exploitable theragnostic potentials. Current Medicinal Chemistry 2015; 22; 1829-49.
Li J et al. Diverse responses to vascular disrupting agent combretastatin a4 phosphate: a comparative study in rats with hepatic and subcutaneous tumor allografts using MRI biomarkers, microangiography, and histopathology. Transl Oncol. 2013; 6(1): 42–50.
Li J et al. A dual-targeting anticancer approach: soil and seed principle. Radiology. 2011; 260(3):799-807.
Li J et al. Exploring theranostic potentials of radioiodinated hypericin in rodent necrosis models. Theranostics. 2012; 2(10):1010–1019.
Li J et al. Sequential systemic administrations of combretastatin A4 Phosphate and radioiodinated hypericin exert synergistic targeted theranostic effects with prolonged survival on SCID mice carrying bifocal tumor xenografts. Theranostics. 2013; 3(2):127-37.
Miranda Cona M et al. An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications. World J Methodology 2013; 3: 45-64.
Miranda Cona M et al. Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation. Pharm Research. 2014; 31: 278-90.
Miranda Cona M et al. Biodistribution and radiation dosimetry of radioiodinated hypericin as a cancer therapeutic. International Journal of Oncology. 2014; 44(3):819-29.
Miranda Cona M et al. Targetability and biodistribution of radioiodinated hypericin: comparison between microdosing and carrier-added preparations. Anti-Cancer Agents in Medicinal Chemistry 2014; 14(6): 852-61.
Miranda Cona M, et al. Sodium cholate, a solubilizing agent for the necrosis avid radioiodinated hypericin in rabbits with acute myocardial infarction. Drug Delivery 2015; 22(3):427-35.
Li J et al. A single-dose toxicity study on non-radioactive iodinated hypericin for a targeted anticancer therapy in mice. Acta Pharmacol Sin. 2012; 33(12): 1549-1556.
Miranda Cona M et al. Improved clearance of radioiodinated hypericin as a targeted anticancer agent by using a duodenal drainage catheter in rats. Experimental Biology and Medicine 2013; 238(12): 437-49.